Contineum Therapeutics, Inc. Class A Common Stock reports a Return on Equity (ROE) of -24.02%.

What is CTNM's dividend yield?

Contineum Therapeutics, Inc. Class A Common Stock offers a dividend yield of 0.00%.

What is CTNM's Quality Score?

Our AI rates CTNM's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CTNM?

Our AI Timing Score for CTNM is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CTNM belong to?

Contineum Therapeutics, Inc. Class A Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Contineum Therapeutics, Inc. Class A (CTNM) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-06-30)

CTNM AI Analysis Summary

Our AI summary for CTNM: Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -24.02%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CTNM

Contineum Therapeutics, Inc. Class A Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology News 88

USD 15.90

-0.03 (-0.19%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-24.0%

ROE

-23.0%

ROA

0.00%

Div Yield

CONTINEUM THERAPEUTICS, INC. CLASS A COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 15.90 Price -0.03 (-0.19%) Day Change	NEWS SCORE: 88

CTNM, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	88
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	15.90
PBV / Sector	2.50 / 44,022.72
Earning Per Share	-1.53

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	3.80 M GREAT
Average 1W Daily Value	5.26 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	45.44 / -1,697.63 GREAT
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-22.99 / 185,260.96
ROA Average (%) / Sector	-19.00 / 36,684.70
ROA Change Average (%) / Sector	-83.77 / 422,221.66
ROE (%) / Sector	-24.02 / 243,762.23
ROE Average (%) / Sector	-32.71 / 48,758.47
ROE Change Average (%) / Sector	-17.46 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:02
Symbol	CTNM
Name	CONTINEUM THERAPEUTICS, INC. CLASS A COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	32.96 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	599.30 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3565 General Atomics Court, San Diego, CA, United States, 92121

Phone: 858 333 5280

Website: https://www.contineum-tx.com

Employees: 51

Sector: Healthcare >> Biotechnology

Description: Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.